Publication

Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study

Journal Paper/Review - Aug 3, 2017

Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes